There will be a live discussion on TMA’s website:
Rituximab in Myositis – Dr. Chester Oddis
NOON/12PM EST (10 AM Mountain).
Dr. Chester Oddis, a founding medical advisory board member of TMA, answers questions about the most ambitious study ever undertaken for a myositis drug. The RIM study focused on Rituximab in treating adults and children who have dermatomyositis or polymyositis. Dr. Oddis, who was the lead investigator for the multi-center study, is a professor of medicine in the department of Rheumatology and Clinical Immunology at the University of Pittsburgh and the director of the fellowship training program there. He has written extensively on the diagnosis and management of patients with myositis.
Note: you need to be a member of TMA to join in with these live chats, but membership is free!!! To join TMA, click here.